RTOG 0924: Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Description of Research
The purpose of this study is to compare the effects of hormone therapy (androgen deprivation) and radiation therapy to the prostate gland and seminal vesicles with hormone therapy and radiation therapy to the whole pelvic body area on you and your prostate cancer to find out which is better.
Jedidiah Monson, M.D.
Patients who are most likely to benefit from androgen deprivation therapy and whole-pelvic radiotherapy, defined as having a significant risk of lymph node involvement (e.g. >15%, based on the Roach formula) and being in one of the following risk groups: